Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 (PANCOLIN)
Status
Conditions
Treatments
Details and patient eligibility
About
Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of patients, neutralizing antibodies are detected. However, the long-term persistence of such protective antibodies is not known.
The investigators will explore patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected.
The investigators will determine whether this persistance varies according to
- the severity of the Covid-19
- a treatment by steroids during the covid-19. This will help to anticipate whether a second wave of infection is possible in a non-naive population.
Full description
Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of patients, neutralizing antibodies are detected. However, the long-term persistence of such protective antibodies is not known.
The investigators will explore adult patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected.
The investigators will determine whether this persistance varies according to
- the severity of the Covid-19 (3 groups: no oxyegn therapy; oxygen therapy of less than 3L/min; oxygen therapy of 3L/min or more)
- a treatment by steroids during the covid-19. Immunocompromised patients will be excluded.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- positive SARS-CoV-2
Exclusion criteria
- age under 18
- immunocompromised at the onset of Covid-19
Trial design
Primary purpose
Allocation
Interventional model
Masking
170 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Olivier Epaulard, MD,PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal